People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at ... Nordisk's once-daily injectable weight loss therapy Saxenda ...

Novo Nordisk (NVO) has initiated a new Phase 3 trial for its next-gen weight loss therapy CagriSema after the Danish ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...